摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,5S)-ethyl 7-(pyridin-3-yl)-3-azabicyclo[3.3.1]non-6-ene-3-carboxylate | 1423074-46-7

中文名称
——
中文别名
——
英文名称
(1R,5S)-ethyl 7-(pyridin-3-yl)-3-azabicyclo[3.3.1]non-6-ene-3-carboxylate
英文别名
ethyl (1R,5S)-7-pyridin-3-yl-3-azabicyclo[3.3.1]non-6-ene-3-carboxylate
(1R,5S)-ethyl 7-(pyridin-3-yl)-3-azabicyclo[3.3.1]non-6-ene-3-carboxylate化学式
CAS
1423074-46-7
化学式
C16H20N2O2
mdl
——
分子量
272.347
InChiKey
NAEDASQBPKYRBA-QWHCGFSZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    42.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Development of a Scalable Synthesis of a Pyridinyl-3-azabicyclononene, a Novel Nicotinic Partial Agonist
    摘要:
    The process research and development of two syntheses of a novel nicotinic partial agonist, TC-8817 ((+)-5), are described. The original Medicinal Chemistry route had multiple flaws, making it unsuitable for further development. A second approach was explored which was more amenable to optimization. The key steps were an intramolecular Lewis acid-promoted cyclization, a dibromination/elimination sequence to provide a vinyl bromide, and subsequent Suzuki coupling with 3-pyridineboronic acid. The overall yield of similar to 3-16% over nine steps was offset by the low cost of goods and ease of synthesis. A major drawback was the need for simulated moving bed chiral separation on the penultimate intermediate to afford the subsequently desired single enantiomer version. A third-generation, asymmetric variation afforded a key intermediate in good yield and enantiomeric purity, providing proof of concept for a more efficient production of the desired (+)-enantiomer.
    DOI:
    10.1021/op400002r
  • 作为产物:
    参考文献:
    名称:
    Development of a Scalable Synthesis of a Pyridinyl-3-azabicyclononene, a Novel Nicotinic Partial Agonist
    摘要:
    The process research and development of two syntheses of a novel nicotinic partial agonist, TC-8817 ((+)-5), are described. The original Medicinal Chemistry route had multiple flaws, making it unsuitable for further development. A second approach was explored which was more amenable to optimization. The key steps were an intramolecular Lewis acid-promoted cyclization, a dibromination/elimination sequence to provide a vinyl bromide, and subsequent Suzuki coupling with 3-pyridineboronic acid. The overall yield of similar to 3-16% over nine steps was offset by the low cost of goods and ease of synthesis. A major drawback was the need for simulated moving bed chiral separation on the penultimate intermediate to afford the subsequently desired single enantiomer version. A third-generation, asymmetric variation afforded a key intermediate in good yield and enantiomeric purity, providing proof of concept for a more efficient production of the desired (+)-enantiomer.
    DOI:
    10.1021/op400002r
点击查看最新优质反应信息

文献信息

  • Synthesis and Screening of Stereochemically Diverse Combinatorial Libraries of Peptide Tertiary Amides
    作者:Yu Gao、Thomas Kodadek
    DOI:10.1016/j.chembiol.2013.01.013
    日期:2013.3
    Large combinatorial libraries of N-substituted peptides would be an attractive source of protein ligands, because these compounds are known to be conformationally constrained, whereas standard peptides or peptoids are conformationally mobile. Here, we report an efficient submonomer solid-phase synthetic route to these compounds and demonstrate that it can be used to create high quality libraries. A model
    N 取代肽的大型组合文库将是蛋白质配体的有吸引力的来源,因为已知这些化合物在构象上受到限制,而标准肽或类肽在构象上是可移动的。在这里,我们报告了这些化合物的有效亚单体固相合成路线,并证明它可用于创建高质量的库。模型筛选实验和命中分析表明立体中心提供的刚性对于高亲和力结合至关重要。
  • Development of a Scalable Synthesis of a Pyridinyl-3-azabicyclononene, a Novel Nicotinic Partial Agonist
    作者:Scott R. Breining、John F. Genus、J. Pike Mitchener、Timothy J. Cuthbertson、Ronald Heemstra、Matt S. Melvin、Gary M. Dull、Daniel Yohannes
    DOI:10.1021/op400002r
    日期:2013.3.15
    The process research and development of two syntheses of a novel nicotinic partial agonist, TC-8817 ((+)-5), are described. The original Medicinal Chemistry route had multiple flaws, making it unsuitable for further development. A second approach was explored which was more amenable to optimization. The key steps were an intramolecular Lewis acid-promoted cyclization, a dibromination/elimination sequence to provide a vinyl bromide, and subsequent Suzuki coupling with 3-pyridineboronic acid. The overall yield of similar to 3-16% over nine steps was offset by the low cost of goods and ease of synthesis. A major drawback was the need for simulated moving bed chiral separation on the penultimate intermediate to afford the subsequently desired single enantiomer version. A third-generation, asymmetric variation afforded a key intermediate in good yield and enantiomeric purity, providing proof of concept for a more efficient production of the desired (+)-enantiomer.
查看更多